Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II weekly TV-1106 in adults with growth hormone deficiency
2012-004975-37Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Nov 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of albusomatropin in growth hormone deficiency (GHD) (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Change from baseline in IGF-I. Started Nov 2012; status: completed.
02
Drugs
albusomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2012-004975-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004975-37.